Celularity begins trial of COVID-19 cell therapy

By The Science Advisory Board staff writers

August 5, 2020 -- Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) for the treatment of COVID-19.

The company was awarded $750,000 by the California Institute for Regenerative Medicine. The funds will be used to evaluate antiviral activities of the cryopreserved product in underserved and disproportionately affected populations with COVID-19.

During the phase I portion, CYNK-001 will be administered intravenously in up to 14 patients in three doses over the course of seven days. Clearance of SARS-CoV-2 and clinical improvement will be evaluated with chest x-ray during the study. The phase II portion will be a randomized, multisite study that will measure multiple doses to determine efficacy and symptom progression.

Celularity received clearance from the U.S. Food and Drug Administration in April to move forward with the study. The University of California, Irvine is the first site to open for patient enrollment.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.